跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
郭 立人
副教授
,
大腸直腸外科
主治醫師
,
臺北醫學大學附設醫院
https://orcid.org/0000-0002-4865-325X
電子郵件
kuolijen
gmail
com
h-index
3227
引文
24
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2023
每年研究成果
概覽
指紋
網路
專案
(1)
研究成果
(72)
類似的個人檔案
(12)
指紋
查看啟用 Li-Jen Kuo 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Rectum Cancer
100%
Surgery
44%
Chemoradiotherapy
31%
Robot-Assisted Surgery
26%
Neoplasm
25%
Systematic Review
25%
Meta-Analysis
25%
Total Mesorectal Excision
23%
Surgical Margin
22%
Learning Curve
22%
Surgeon
21%
Operation Duration
19%
Colorectal Cancer
18%
Disease
18%
Chemoradiation Therapy
16%
Sphincter
15%
Disease Free Survival
15%
Pooled Analysis
14%
Laparoscopy
14%
Minimally Invasive Surgery
13%
Histopathology
13%
Metastatic Carcinoma
13%
Cancer Surgery
12%
Malignant Neoplasm
12%
Stoma
12%
Colorectal Surgery
12%
Laparoscopic Surgery
12%
Randomized Controlled Trial
11%
Recurrent Disease
9%
Rectum Surgery
9%
Meta-Regression
9%
Feces Incontinence
9%
Inguinal Hernia
9%
Colon Cancer
9%
Rectum Resection
9%
Overall Survival
8%
Surgical Technique
8%
Patient-Data
8%
Magnetic Resonance Imaging
8%
Pelvis
7%
Drug Therapy
7%
Biopsy
7%
Hernioplasty
7%
Reoperation
7%
Fluorouracil
7%
Rectum Carcinoma
7%
Quality of Life
6%
Bleeding
6%
Hepatocellular Carcinoma
6%
Treatment Response
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rectum Cancer
29%
Chemoradiation Therapy
27%
Malignant Neoplasm
15%
Chemotherapy
15%
Neoplasm
13%
Glucose Regulated Protein 78
13%
Survivin
13%
Bevacizumab
13%
Liver Cell Carcinoma
11%
Cisplatin
9%
Gemcitabine
9%
Fibronectin
9%
Stomach Cancer
9%
Colon Cancer
9%
Cetuximab
9%
Recurrent Disease
8%
Overall Survival
8%
Pancreas Cancer
8%
Disease Free Survival
7%
Metastasis
7%
Colorectal Cancer
6%
Fluorouracil
6%
Small Interfering RNA
6%
Bungarotoxin Receptor
6%
Disease
5%
Combination Therapy
5%
Nicotinic Receptor
5%
Nursing and Health Professions
Systematic Review
10%
Meta Analysis
9%
Feces Incontinence
9%
Colorectal Cancer
9%
Malignant Neoplasm
6%
Metastasis
6%
Quality of Life
5%
